What "Secret Shoppers" Found Inside the Compounded GLP-1 Market

A patient called the office last winter to ask whether the weight-loss injection she was buying online was the same as the one her cousin was getting through her insurance. The price was a third of what her cousin was paying. The vials looked similar. The website mentioned a "compounding pharmacy partner." She wanted to know if she should be worried. The answer, in a phrase, is yes.

Photo: Clay Banks / Unsplash

A new study presented this April at the Obesity Medicine Association 2026 meeting put hard numbers on what many clinicians have been observing without much fanfare for two years now. Compounded GLP-1 weight-loss products, the kind sold through medical spas, telehealth clinics, and online weight-loss services, are still widely available, often contain undisclosed additives, and are frequently sourced from facilities with significant gaps in their sterile-compounding oversight.

What the research found

Researchers from the University of Colorado Anschutz Medical Campus, led by health policy researcher Michael DiStefano, ran a "secret shopper" investigation in two states with high obesity rates and limited Medicaid coverage for weight-loss medications. They contacted 75 weight-loss clinics and medical spas advertising compounded versions of semaglutide and tirzepatide, the two most popular GLP-1 receptor agonist medications. Of the 58 facilities that answered the question about additives, 44 said they were selling formulations that included extras such as B vitamins, levocarnitine, and glycine, often marketed as energy boosters or nausea reducers.

Then the researchers cross-referenced 23 of the source compounding facilities against state and FDA licensing records. Nearly all were licensed at some level. Yet of the 21 traditional pharmacies in that group, only 17 were licensed for sterile compounding, the higher-bar certification that injectable medications actually require. Four facilities had received FDA or state board disciplinary actions since 2023, three of those tied directly to sterile compounding violations.

In other words, patients were paying for an injectable peptide drug, often blended with other ingredients, sometimes manufactured by facilities that weren't authorized to produce sterile injectables in the first place. Reporter Miriam Tucker covered the findings for Medscape on April 20, 2026.

The study itself is a conference presentation, so the full peer-reviewed paper isn't yet out. The findings are consistent, however, with a 2025 pharmacovigilance analysis published in Expert Opinion on Drug Safety. That study reviewed FDA Adverse Event Reporting System data from 2018 through 2024 for liraglutide, semaglutide, and tirzepatide. Of more than 81,000 reports involving these drugs, 707 specifically involved compounded versions. Compared to the brand-name products, compounded GLP-1s showed higher reporting odds of preparation errors (about 49-fold), contamination (19-fold), and hospitalization (about 2.4-fold). They also showed higher reporting odds for adverse events such as abdominal pain, nausea, cholecystitis, and signals related to suicidality. Reporting odds ratios aren't the same as causal estimates, so these numbers tell us that something is showing up disproportionately in compounded-product reports. They can't prove the compounding itself is the cause.

Where this fits in the regulatory landscape

It helps to understand the regulatory back-story. When demand for these drugs first exploded in 2022, the FDA placed both semaglutide and tirzepatide on its drug-shortage list, which legally allowed compounding pharmacies to make versions during the supply crisis. Once Novo Nordisk and Eli Lilly stabilized their supply chains in early 2025, the FDA pulled both drugs off the shortage list and clarified that mass-produced "essentially identical" compounded copies were no longer permitted. Pharmacies are still allowed to make patient-specific formulations, the kind a clinician orders for someone with a documented allergy or a swallowing difficulty. The DiStefano team's findings suggest that some businesses are leaning hard on the patient-specific exception by adding B vitamins or glycine to a base GLP-1 and treating the result as a custom product.

That gray area is where the safety risk lives. Compounded products aren't subject to the same FDA review for safety, efficacy, or quality as brand-name versions. They aren't necessarily wrong or inferior in every case, but the variability is real, and the patient is the one absorbing it.

The naturopathic perspective

Patients aren't running toward compounded products because they want second-tier medicine. They're running toward whatever they can afford, whatever they can access without insurance hurdles, whatever feels like a path forward when nothing else has worked. The system is failing them at the front end, and the secondary market is filling the gap with mixed motives and uneven quality.

When I sit with a patient who is exploring or already using one of these medications, the conversation is rarely about whether the drug "works." It usually does, in the narrow sense of producing weight loss. The conversation worth having is about the rest of the metabolic picture. What is the underlying terrain? Are we looking at insulin resistance, chronic inflammation, hormonal disruption, gut dysbiosis, sleep deprivation, chronic stress, or some combination? Because a GLP-1 agonist is a powerful metabolic tool, and powerful tools work better when the foundation underneath them has been addressed too. Otherwise the drug can do its job, the weight can come down, and the underlying drivers stay intact and unaddressed.

The other piece worth saying out loud: when patients lose meaningful weight on these medications, they also lose lean mass, especially without protein adequacy and resistance training. That ties directly back into the conversation about sarcopenia and falls in older adults, the conversation about hormones and bone density in midlife women, and the broader naturopathic principle of supporting the whole organism rather than chasing one number.

How to apply this now

If you're using a compounded GLP-1, or considering one, a few practical pieces matter. First, ask your prescriber where the compounded medication is being made. The facility's name is fair to ask for, and you can verify it against state pharmacy board records and the FDA's enforcement database. Second, ask what is in the formulation beyond the active drug. If the product contains additives, ask why those additives are there for you specifically rather than as a generic upgrade. Third, look specifically for sterile compounding licensure rather than just any pharmacy license. Sterile injectables require a higher standard. Fourth, if you're working with any healthcare provider on weight, build the foundation alongside the medication: protein adequacy, resistance training, sleep, nutrient status, blood-sugar stability, and stress management. The drug is doing one job. You can do the rest of the work that makes the result durable.

And if affordability is the actual driver, ask your prescriber about generic injectable semaglutide options expected this year in some markets, the manufacturer's direct-pay programs, or whether your insurance picture has changed since you last checked. Sometimes the safer path costs less than people assume.

References

1. Tucker ME. 'Secret Shopper' Study Finds Risks in Compounded GLP-1s. Medscape Medical News. April 20, 2026. https://www.medscape.com/viewarticle/secret-shopper-study-finds-risks-compounded-glp-1s-2026a1000car. Reporting on conference findings presented by DiStefano MJ et al. at the Obesity Medicine Association 2026 meeting.

2. McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. 2025;25(3):581-588. PMID: 40285721. DOI.

3. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize.

A note before you go

This is for educational purposes and is not a substitute for working with a provider who knows your history. If you are using or considering a GLP-1 medication of any kind, please loop in your prescribing clinician before making changes, and ask the questions above before starting a compounded product.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.